Boehringer Ingelheim is sponsoring a collaborative research project with the American Diabetes Association to improve the evidence base for and clinical care of patients with chronic kidney disease and diabetes.
The three-year commitment includes $1.5 million from Boehringer, which will be managed by the ADA.
“Diabetes is the leading cause of kidney failure, accounting for more than 40% of new cases,” the American Diabetes Association’s president of medicine and science Elizabeth Seaquist said in a statement.
